Home > Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia
Leukaemia

Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia

Published Online: December 18th 2019

At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia.

Questions

1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05)

2. Following discontinuation of TKIs in patients with CML, when are relapses most likely to occur? (1:20)

3. What are the current recommendations for monitoring patients following TKI discontinuation? (1:40)

4. What factors predict which patients are likely to relapse? (2:39)

5. Could you tell us a little about your study, its findings and their implications? (3:24)

 

Massimo Breccia has no conflicts of interest to declare in relation to this video.

Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.

Related Videos In Leukaemia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar